

10/755,545

Sequence alignment B

SEQ ID NO:2

AA01098

ID AA01098 standard; protein; 263 AA.

XX

AC AA01098;

XX

DT 15-JUN-2007 (revised)

DT 11-JUN-1999 (first entry)

XX

DE Human follistatin-3 protein sequence.

XX

KW Follistatin-3; human; cancer; cellular growth disorder; liver cirrhosis;
KW differentiation disorder; reproductive system disorder; male sterility;
KW activin-induced differentiation inhibitor; gonadotroph adenoma; hepatoma;
KW osteosarcoma; idiopathic pulmonary fibrosis; pulmonary fibrosis; tumour;
KW fibrotic disorder; osteoarthritis; haematopoiesis; infectious disease;
KW sepsis; cancer; silicosis; sarcoidosis; endotoxic shock; therapy;
KW BOND_PC; follistatin-like 3 glycoprotein; follistatin-related protein;
KW follistatin-like 3 glycoprotein [Homo sapiens]; FSTL3; FLRG; FSRP;
KW follistatin-like 3 glycoprotein precursor;
KW follistatin-like 3 glycoprotein;
KW follistatin-like 3 glycoprotein precursor [Homo sapiens];
KW follistatin-like 3 (secreted glycoprotein), isoform CRA_a;
KW follistatin-like 3 (secreted glycoprotein), isoform CRA_a [Homo sapiens];
KW FSTL3 [Homo sapiens]; follistatin-like 3 (secreted glycoprotein);
KW Follistatin-like 3 (secreted glycoprotein) [Homo sapiens];
KW follistatin-related protein FLRG;
KW follistatin-related protein FLRG [Homo sapiens]; GO5615; GO17106;
KW GO30514; GO48185; GO8151.

XX

OS Homo sapiens.

XX

PN WO9910364-A1.

XX

PD 04-MAR-1999.

XX

PF 27-AUG-1998; 98WO-US017710.

XX

PR 29-AUG-1997; 97US-0056248P.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Ruben SM, Duan R;

XX

DR WPI; 1999-204646/17.

DR N-PSDB; AAX28124.

DR PC:NCBI; gi5031701.

DR PC:SWISSPROT; O95633.

XX

PT New follistatin-3 polypeptides and nucleic acids - used to develop
PT products for treating e.g. cancers, male sterility, wound healing,
PT fibrotic disorders, angiogenesis and autoimmune, inflammatory and
PT infective diseases.

XX

PS Claim 18; Fig 1; 109pp; English.

XX

CC This sequence is the follistatin-3 (FS3) protein of the invention. The
CC products can be used to treat cancers and other cellular growth and
CC differentiation disorders as well as disorders of the reproductive
CC system. FS3 can be used or to treat male sterility. FS3 may also be used
CC to inhibit the activin-induced differentiation of follicular granulosa
CC cells. FS3 may be used therapeutically to regulate autocrine endothelial
CC cell activity and, as a result, induce angiogenesis. Treatment to
CC increase the expression or the presence of FS3 may be used to inhibit the
CC progression of gonadotroph adenomas, osteosarcomas, hepatomas, and other
CC tumours and cancers. FS3 may also be used to treat other fibrotic
CC disorders including liver cirrhosis, osteoarthritis and pulmonary
CC fibrosis. It may also be used to regulate haematopoiesis, and to treat

CC sepsis. Antagonists of FS3 may be used to treat a deficiency in FSH,
CC oestrogen and other hormones, to prevent or inhibit or reduce the
CC production of spermatozoa, to modulate gonadal androgen biosynthesis. FS3
CC antagonists may also be used to treat infectious diseases including
CC silicosis, sarcoidosis, idiopathic pulmonary fibrosis by altering the
CC activation state of mononuclear phagocytes, to treat idiopathic hyper-
CC eosinophilic syndrome by preventing eosinophil production and activation.
CC Endotoxic shock may also be treated by FS3 antagonists by preventing the
CC activation of macrophages
CC
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC information from BOND.
XX
SQ Sequence 263 AA;

Query Match 100.0%; Score 1492; DB 2; Length 263;
Best Local Similarity 100.0%; Pred. No. 3.3e-104;
Matches 263; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRPGAPGPLWPLPWGALAWAVGFVSSMSGGNPAPGGVCWLQQGQEATCSLVLQTDVTRAE 60
|
Db 1 MRPGAPGPLWPLPWGALAWAVGFVSSMSGGNPAPGGVCWLQQGQEATCSLVLQTDVTRAE 60

Qy 61 CCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVCEGPGKACRMLGGRPRCE 120
|
Db 61 CCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVCEGPGKACRMLGGRPRCE 120

Qy 121 CAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLSVMYRGRCRKSCEHVVCPRPQ 180
|
Db 121 CAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLSVMYRGRCRKSCEHVVCPRPQ 180

Qy 181 SCVVDQTGSAHCVVCRAAPCPVPSSPGQELCGNNNVTYISSCHMRQATCFLGRSIGVRHA 240
|
Db 181 SCVVDQTGSAHCVVCRAAPCPVPSSPGQELCGNNNVTYISSCHMRQATCFLGRSIGVRHA 240

Qy 241 GSCAGTPEEPPGGESAEEEEENFV 263
|
Db 241 GSCAGTPEEPPGGESAEEEEENFV 263